The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study

被引:8
|
作者
Gorur, Kemal [1 ]
Gur, Harun [1 ]
Ismi, Onur [1 ]
Ozcan, Cengiz [1 ]
Vayisoglu, Yusuf [1 ]
机构
[1] Mersin Univ, Sch Med, Dept Otorhinolaryngol, Mersin, Turkey
关键词
Botulinum toxin; Vestibular migraine; Vestibular migraine treatment; PLACEBO-CONTROLLED PHASE; DOUBLE-BLIND; ONABOTULINUMTOXINA; VERTIGO; DIZZINESS; HISTORY;
D O I
10.1016/j.bjorl.2021.02.005
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Introduction: Vestibular migraine is the most common cause of spontaneous episodic vertigo in adult patients and the second most common cause of vertigo in patients of all ages. Objective: To assess the effectiveness of oral medication type (propranolol, flunarizine, and amitriptyline) and botulinum toxin A application on vestibular symptoms, headache severity and attack frequency for vestibular migraine patients. Methods: Sixty patients with vestibular migraine were enrolled. Thirty patients received botulinum toxin A treatment (B+ group) in addition to the oral medication, whereas 30 patients received only oral medication (B- group). Headache severity was evaluated with Migraine Disability Assessment Scale and vertigo severity was evaluated with Dizziness Handicap Inventory scale. Vestibular migraine attack frequencies in the last three months were also evaluated. Results: There was a statistically significant decrement in mean Dizziness Handicap Inventory scores, Migraine Disability Assessment Scale scores and vertigo attack frequencies after treatment for all patients, B+ and B- group patients (p < 0.001 for all). The mean Migraine Disability Assessment Scale score gains (p < 0.001) and vertigo attack frequency gains (p= 0.003) were significantly higher in the B+ patients than B- patients. Conclusions: Both B+ and B- group patients exhibited significant improvement in vestibular migraine attack frequencies, Dizziness Handicap Inventory score and Migraine Disability Assessment Scale score values. However, botulinum toxin A application had a more pronounced effect for Migraine Disability Assessment Scale score gain and vestibular migraine attack frequency values, but not for Dizziness Handicap Inventory score gain values. Thus, botulinum toxin A application should be considered for vestibular migraine patients whose headache severity degrees are more profound. The oral medication type (propranolol, flunarizine or amitriptyline) did not differ in influencing the vestibular migraine attack frequency, Dizziness Handicap Inventory score gain and Migraine Disability Assessment Scale score gain values.
引用
收藏
页码:975 / 981
页数:7
相关论文
共 50 条
  • [1] Propranolol and Venlafaxine for Vestibular Migraine Prophylaxis: A Randomized Controlled Trial
    Salviz, Mehti
    Yuce, Turgut
    Acar, Hurtan
    Karatas, Abdullah
    Acikalin, R. Murat
    [J]. LARYNGOSCOPE, 2016, 126 (01): : 169 - 174
  • [2] Effectiveness of botulinum toxin type-A in the treatment of migraine headache: A randomized controlled trial
    LaButta, R
    Sartori, R
    Vo, A
    Green, J
    Campbell, W
    Jabbari, B
    [J]. NEUROLOGY, 2005, 64 (06) : A335 - A335
  • [3] A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type a for migraine prophylaxis
    Elkind, Arthur H.
    O'Carroll, Philip
    Blumenfeld, Andrew
    DeGryse, Ronald
    Dimitrova, Rozalina
    [J]. JOURNAL OF PAIN, 2006, 7 (10): : 688 - 696
  • [4] The Efficacy and Safety of Acupuncture for Prophylaxis of Vestibular Migraine: A Study Protocol for a Randomized Controlled Trial
    Hu, Tianye
    Hu, Hantong
    Chen, Feng
    Jiang, Bin
    Shen, Fengfei
    Su, Yingying
    Yang, Mengyi
    Hu, Jin
    [J]. FRONTIERS IN NEUROLOGY, 2021, 12
  • [5] Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study
    Millan-Guerrero, R. O.
    Isais-Millan, S.
    Barreto-Vizcaino, S.
    Rivera-Castano, L.
    Rios-Madariaga, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (01) : 88 - 94
  • [6] Botulinum Toxin Type A (DYSPORT) as a prophylactic treatment of migraine: A double blind, randomized, placebo controlled study
    Sikaroodi, H.
    Lotfi, J.
    Fathi, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 13 - 13
  • [7] Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study
    Evers, S
    Vollmer-Haase, J
    Schwaag, S
    Rahmann, A
    Husstedt, IW
    Frese, A
    [J]. CEPHALALGIA, 2004, 24 (10) : 838 - 843
  • [8] Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a non-randomized controlled trial
    Adnan Giral
    Kemal Memişoğlu
    Yücel Gültekin
    Neşe İmeryüz
    Cem Kalaycı
    Nefise B Ulusoy
    Nurdan Tözün
    [J]. BMC Gastroenterology, 4
  • [9] A prospective, controlled, non-randomized study of three cohorts to test the effectiveness of two antibiotics levofloxacin and cotrimoxazol on antibacterial prophylaxis in neutropenic patients
    Escudero, AG
    González, MM
    Garrido, FG
    Farré, CC
    Pérez, MJG
    Corral, GA
    Bertos, AR
    Maldonado, GV
    Cuartero, AR
    [J]. MEDICINA CLINICA, 2003, 120 (09): : 321 - 325
  • [10] A randomised, controlled, 3-study series of multiple treatments with low doses of botulinum toxin type A for the prophylaxis of episodic migraine
    Elkind, AH
    O'Carroll, CR
    Blumenfeld, A
    DeGryse, R
    Dimitrova, R
    [J]. JOURNAL OF NEUROLOGY, 2005, 252 : 103 - 104